李氏大藥廠股票討論區

Despite a surge in Lee's Pharmaceutical's stock, a modest P/S ratio remains due to expected weak growth. Declining revenue fuels shareholder pessimism and the firm needs a significant turnaround to justify a higher P/S ratio.